Zydus Lifesciences (ZYDUSLIFE) — Announcement

📢 Key Event
Zydus Lifesciences schedules investor conference August 24-26, 2026

🔄 What Changed
Revenue grew 13.5% CAGR to FY26, PAT margin reached 23.5%

🔮 What's Next
NDA submission for Saroglitazar targeting Q4 FY27 approval

💡 Investor Takeaway
Investors should monitor biosimilar and vaccine pipeline progress for future growth catalysts.

Zydus Lifesciences announced an investor conference from August 24-26, 2026, showcasing its financial performance and growth strategy. The company reported FY26 revenue of ₹3,020 crores with ₹1,170 crores EBITDA, reflecting 13.5% CAGR and 23.5% PAT margin. Key growth drivers include biosimilars, vaccines, and US generics expansion, supported by 8.4% revenue R&D investment and a 71-product pipeline. Strategic acquisitions like Comfort Click bolster its digital and global footprint, positioning it as India's top oncology biosimilar player and a global vaccine innovator.

📄 View Original Announcement (PDF)

📊 Stock Analysis — ZYDUSLIFE ✨ Ask AI About This

About Zydus Lifesciences Limited (ZYDUSLIFE)

Healthcare · Pharmaceuticals · Listed on NSE

Market Cap: ₹1,15,919.92 Cr P/E: 25.9 ROE: 16.6% ROCE: 16.8% Div Yield: 0.09%

View full ZYDUSLIFE stock details →

📡 Get AI alerts when ZYDUSLIFE files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track ZYDUSLIFE — Free

💡 Ask AI about this filing

"How will biosimilar approvals impact revenue growth?" "What is the timeline for Saroglitazar's US FDA approval?" "How does Comfort Click acquisition affect international expansion?"

Ask AI Free →

📊 More ZYDUSLIFE filings

See all ZYDUSLIFE filings →

🔥 Also filed on 23 August 2026

MEESHO Meesho Limited Board Meeting GUJTHEM Gujarat Themis Biosyn Limited Voting Results PRITI Priti International Limited Board Meeting DONEAR Donear Industries Limited Board Meeting PNC Pritish Nandy Communications Limited Voting Results

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when ZYDUSLIFE files new disclosures

Track ZYDUSLIFE filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track ZYDUSLIFE — Free

Free account · 2 AI queries/day

About · Privacy Policy · Terms of Service · Pricing

Today's Announcements · Screener · Insights · AI Chat

Data provided by CMOTS Internet Technologies Pvt Ltd